Latest Conference Articles

Data from the CheckMate 648 trial informed the FDA’s recent approval of 2 nivolumab combinations for esophageal squamous cell carcinoma. A 1-year follow-up analysis highlighted key safety and time-to-event data surrounding immune-related toxicities.

Mandible reconstruction and maxilla reconstruction surgeries might be optimized with virtual surgical planning, according to an expert speaker at the 2022 Supportive Care in Cancer Annual Meeting.

We rounded up 5 stories from the 2022 ASCO Annual Meeting that are of most value to oncology nurses.

Results of a single-center study presented at the 2022 ASCO Annual Meeting showed that oral minoxidil may be effective in treating late alopecia. Moving forward, these efforts in survivorship care will need to be expanded to less resourced areas, experts said.

At the 2022 Supportive Care in Cancer Annual Meeting, Jeffrey Crawford, MD, highlighted the potential value of biosimilars in reducing gaps in care for the treatment of febrile neutropenia.

Data from the phase 1/2 EPCORE NHL-2 trial suggest that the combination of epcoritamab and R-CHOP is both effective and manageable in treating patients with high-risk diffuse large B-cell lymphoma.

Updated data from the phase 3 BELIEVE trial revealed a sustained reduction in the need for red blood cell transfusions among patients with β-thalassemia who received treatment with luspatercept-aamt.

This year’s congress showcased strategies for communicating sensitive topics, patient experiences with immunotherapy treatments, updates in the utility of medical cannabis, and more.

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, recounts key nursing considerations with targeted therapy for chronic lymphocytic leukemia, and third-line diffuse large b-cell lymphoma options.

Heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia maintained response with tisagenlecelucel according to long-term follow-up data from the phase 2 ELIANA trial.

The intracranial objective response rate was 32% among patients with KRAS G12C–mutant, non–small cell lung cancer who received adagrasib.

Phase 2 findings found that patients with chemotherapy-induced anemia experienced increases in hemoglobin following treatment with roxadustat.

Aliènne Salleroli, MS, BSN, RN, OCN, underscores the importance of open dialogue surrounding diversity, equity, and inclusion in oncology leadership.

Daratumumab plus lenalidomide and dexamethasone bested standard therapy in producing rapid, deep, and durable responses across subgroups of patients with newly diagnosed multiple myeloma.

Phase 3 findings showed that panitumumab plus mFOLFOX significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer.

Regardless of other identified driver genomic alterations, patients with heavily pretreated, advanced, non–small cell lung cancer achieved encouraging responses with patritumab deruxtecan.

Patients with recurrent C difficile infection receiving SER-109 experienced reduced rates of infection as early as 4 weeks following treatment.

A real-world analysis showed that the proportion of women with ovarian cancer who required dose modifications or treatment discontinuations while receiving PARP inhibitors differed significantly between olaparib, niraparib, and rucaparib.

Ilene Galinsky, BSN, MSN, ANP-C, senior leukemia protocol research nurse practitioner at Dana-Farber Cancer Institute, underscores key prescribing considerations with venetoclax.

Patients with hormone receptor¬–positive, HER2-negative, node-positive high-risk early breast cancer who have certain characteristics may benefit from early dose adjustments with adjuvant abemaciclib.

Ken Kato, MD, PhD, a medical oncologist at the National Cancer Center of Tokyo, and investigator in the pivotal CheckMate 648 study, underscores relevant safety data updates from the trial and important symptom management considerations with the FDA-approved combinations.

Frontline nivolumab and ipilimumab combination therapy was associated with increased 5-year survivorship in patients with metastatic non–small cell lung cancer—regardless of PD-L1 expression.

Ovarian clear cell carcinoma is a rare histological type of epithelial ovarian cancer that is typically resistant to chemotherapy and is historically associated with poor prognosis for patients.

Elderly patients receiving novel-androgen hormonal therapies, such as abiraterone and enzalutamide, listed forgetfulness as their No. 1 reason for not taking prescribed pills.

Relatlimab, a human LAG-3 blocking antibody, plus nivolumab, elicited superior progression-free survival in patients with advanced melanoma compared to nivolumab alone.

Investigators reported an objective response rate of 43% and a disease control rate of 80% among patients with previously treated KRAS G12C–mutated non–small cell lung cancer who received the KRAS G12C inhibitor adagrasib.

Frontline treatment with lenvatinib plus pembrolizumab decreased risk of disease progression or death by 50% compared with sunitinib in advanced renal cell carcinoma.

At data cutoff, all treated patients in a phase 2 trial experienced a clinical complete response with single-agent dostarlimab-gxly.